Gemcitabine versus FOLFIRINOX in patients with advanced hENT1+ve pancreatic adenocarcinoma.

e15295 Background: Human equilibrative nucleoside transporter 1 (hENT1) is a transmembrane protein which acts as a nucleoside transporter and represents the main mediator of gemcitabine (GEM) uptake into human cells. Several studies showed a possible role of hENT1 expression as a predictor of response to GEM in pancreatic adenocarcinoma (PAC) mainly in adjuvant setting. For the first time, in this retrospective study we compared GEM versus FOLFIRINOX in a selected population affected by advanced PAC (a-PAC) hENT1 positive (hENT1+ve). Methods: 149 patients affected by a-PAC, treated at our institution from 2009 to 2013, have been screened in this retrospective study. 71 patients, treated with GEM or FOLFIRINOX first line therapy, fulfilled clinical inclusion criteria for survival analysis. 31 patients, whose stored tumor samples were available and contained sufficient DNA for hENT1 expression by RT-PCR, underwent exploratory analysis. The primary endpoint was OS and the secondary endpoint was PFS. Grade 3-...